TGFBR2

TGFBR2
Name	TGFBR2
Altnames	TGF-β receptor type II
Omim	190182
Uniprot	P37173

TGFBR2 The transforming growth factor beta receptor type II is a single-pass transmembrane serine/threonine kinase implicated in cellular proliferation, differentiation, and extracellular matrix production. Originally characterized in studies from laboratories associated with National Institutes of Health, Harvard University, and Cold Spring Harbor Laboratory, the receptor mediates signaling by ligands of the Transforming growth factor beta family and interacts with intracellular effectors to influence developmental and pathological processes. Research on this receptor spans collaborations involving institutions such as Massachusetts Institute of Technology, Stanford University, and pharmaceutical companies including Pfizer and Roche.

Introduction

TGFBR2 encodes a type II receptor that binds ligands from the Transforming growth factor beta family, including TGF-β1, TGF-β2, and TGF-β3, initiating cascades that involve SMAD proteins first characterized in work from Max Planck Society and University of California, San Francisco. Early molecular cloning efforts were reported by groups at University of Cambridge and Yale University, while structural insights were advanced through cryo-EM studies at European Molecular Biology Laboratory and Riken. Clinical research linking receptor dysfunction to syndromes was conducted at centers such as Mayo Clinic and Johns Hopkins Hospital.

Structure and Function

The receptor is a homodimeric transmembrane protein with an extracellular ligand-binding domain, a transmembrane helix, and an intracellular serine/threonine kinase domain similar to kinases described in Protein kinase A studies at Weizmann Institute of Science. Structural models draw on crystallography efforts from European Synchrotron Radiation Facility and computational predictions by teams at DeepMind and Stanford University. Upon ligand binding, the type II receptor phosphorylates type I receptors such as those identified in Cell Press publications, enabling recruitment and phosphorylation of receptor-regulated SMADs (R-SMADs) characterized in research at Cold Spring Harbor Laboratory and Salk Institute. Functional assays performed by laboratories at National Cancer Institute and Dana-Farber Cancer Institute demonstrated roles in epithelial-to-mesenchymal transition studies also pursued at Memorial Sloan Kettering Cancer Center.

Clinical Significance

Mutations and dysregulation of the receptor are implicated in familial and sporadic disorders examined in cohorts from Cleveland Clinic and University College London. Pathogenic variants are associated with conditions such as hereditary hemorrhagic telangiectasia-like vascular syndromes evaluated at Mayo Clinic and with tumorigenesis in malignancies profiled by American Cancer Society reports. Tumor suppressor functions were highlighted in work at Cold Spring Harbor Laboratory, and targeted therapeutics were developed in trials run by National Cancer Institute and companies like Novartis and AstraZeneca. The receptor’s involvement in fibrotic diseases prompted clinical studies at University of Pennsylvania and Imperial College London.

Regulation and Signaling Pathways

Receptor activity is modulated by coreceptors and accessory molecules characterized at Max Planck Institute and Broad Institute, and by endocytic trafficking pathways elucidated by groups at MIT and University of Oxford. Downstream signaling integrates SMAD-dependent transcriptional programs with non-SMAD pathways involving MAPK cascades studied in labs at Cold Spring Harbor Laboratory and Hopkins Medical Institutions. Crosstalk with pathways described in research from Howard Hughes Medical Institute and Wellcome Trust-funded groups links receptor function to WNT signaling investigations at University of Cambridge and to NOTCH pathway studies at Karolinska Institutet.

Genetic Variants and Mutations

Clinical genetics consortia including ClinVar-linked studies and registries maintained by Human Genome Organization and European Society of Human Genetics catalog variants discovered by sequencing centers at Broad Institute and Wellcome Sanger Institute. Loss-of-function, missense, and frameshift variants have been reported in case series from Johns Hopkins Hospital, Mount Sinai Health System, and Royal Marsden Hospital. Population genetics analyses using data sets from 1000 Genomes Project and Exome Aggregation Consortium clarified allele frequencies, while functional validation of variants was performed at laboratories affiliated with University of Toronto and Utrecht University.

Model Organism Studies

Mouse models engineered at facilities such as Jackson Laboratory and European Mouse Mutant Archive recapitulate aspects of human pathology and were used in preclinical studies at Salk Institute and MRC Harwell. Zebrafish and Xenopus studies led by researchers at University of Oregon and École Normale Supérieure illuminated developmental roles, while Drosophila models in labs at University of Cambridge offered insights into conserved signaling modules. Knockout and conditional alleles generated in collaborations with CRISPR Therapeutics-linked groups and university core facilities have been instrumental in dissecting tissue-specific functions and therapeutic interventions tested by teams at Dana-Farber Cancer Institute and Vanderbilt University.

Category:Human proteins